Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective
As the new SARS-CoV-2 Omicron variants and subvariants emerge, there is an urgency to
develop intranasal, broadly protective vaccines. Here, we developed highly efficacious …
develop intranasal, broadly protective vaccines. Here, we developed highly efficacious …
Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and …
Serum titers of SARS-CoV-2-neutralizing antibodies (nAbs) correlate well with protection
from symptomatic COVID-19 but decay rapidly in the months following vaccination or …
from symptomatic COVID-19 but decay rapidly in the months following vaccination or …
A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a …
J Brunet, Z Choucha, M Gransagne, H Tabbal… - Journal of …, 2024 - Am Soc Microbiol
In the early COVID-19 pandemic with urgent need for countermeasures, we aimed at
developing a replicating viral vaccine using the highly efficacious measles vaccine as …
developing a replicating viral vaccine using the highly efficacious measles vaccine as …
Negative-Strand RNA Virus-Vectored Vaccines
M Murr, T Mettenleiter - RNA Vaccines: Methods and Protocols, 2024 - Springer
Vectored RNA vaccines offer a variety of possibilities to engineer targeted vaccines. They
are cost-effective and safe, but replication competent, activating the humoral as well as the …
are cost-effective and safe, but replication competent, activating the humoral as well as the …
Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice
S Slamanig, I González-Domínguez, LA Chang… - …, 2024 - thelancet.com
Background In order to prevent the emergence and spread of future variants of concern of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), developing vaccines …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), developing vaccines …
A murine model of post-acute neurological sequelae following SARS-CoV-2 variant infection
Viral variant is one known risk factor associated with post-acute sequelae of COVID-19
(PASC), yet the pathogenesis is largely unknown. Here, we studied SARS-CoV-2 Delta …
(PASC), yet the pathogenesis is largely unknown. Here, we studied SARS-CoV-2 Delta …
Finally neutralizing the threat? A novel SARS-CoV-2 vaccine platform that elicits enhanced neutralizing antibody responses
DJ Salamango - Mbio, 2024 - Am Soc Microbiol
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak took the
world by storm due to its rapid global spread and unpredictable disease outcomes. The …
world by storm due to its rapid global spread and unpredictable disease outcomes. The …
Measles Virus-Based Vaccine Expressing Membrane-Anchored Spike of SARS-CoV-2 Inducing Efficacious Systemic and Mucosal Humoral Immunity in Hamsters
ZH Yang, YL Song, J Pei, SZ Li, RL Liu, Y Xiong, J Wu… - Viruses, 2024 - mdpi.com
As SARS-CoV-2 continues to evolve and COVID-19 cases rapidly increase among children
and adults, there is an urgent need for a safe and effective vaccine that can elicit systemic …
and adults, there is an urgent need for a safe and effective vaccine that can elicit systemic …
Engineered influenza viruses expressing sars-cov-2 antigens, vaccines and methods of making and using the same
N Heaton, A Harding, B Heaton… - US Patent App. 18 …, 2024 - Google Patents
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN [C@ H] 1
[C@ H](O)[C@@ H](O)[C@ H](CO) O [C@ H] 1O [C@@ H] 1 [C@](C= O)(O)[C@ H](C) O …
[C@ H](O)[C@@ H](O)[C@ H](CO) O [C@ H] 1O [C@@ H] 1 [C@](C= O)(O)[C@ H](C) O …